Search results
AstraZeneca withdrawing Covid vaccine, months after admitting rare side effect
The Telegraph via Yahoo News· 4 hours agoThe Oxford-AstraZeneca Covid vaccine is being withdrawn worldwide, months after the pharmaceutical...
Moderna Shares Jump After Better-Than-Expected Sales
The Wall Street Journal· 5 days agoModerna shares shot up about 7% Thursday after reporting better-than-expected quarterly sales and signaling confidence in a sales pickup later this year....
Moderna (NASDAQ:MRNA) PT Raised to $106.00
ETF DAILY NEWS· 23 hours agoModerna (NASDAQ:MRNA – Free Report) had its price target increased by Canaccord Genuity Group from $91.00 to $106.00 in a report published on Friday, Benzinga reports. Canaccord ...
Fauci, other top health officials receive Moderna Covid-19 vaccine on camera
AOL· 12 hours agoFauci, director of the National Institute of Allergy and Infectious Diseases, received the shot...
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Zacks via Yahoo Finance· 2 weeks agoModerna (MRNA) closed the most recent trading day at $107.97, moving +1.69% from the previous...
Should You Buy Moderna Before May 12?
Motley Fool via Yahoo Finance· 2 weeks agoModerna (NASDAQ: MRNA) stock soared earlier in the pandemic as the company developed its coronavirus vaccine and the product went on to generate billions...
Check Out What Whales Are Doing With MRNA - Moderna (NASDAQ:MRNA)
Benzinga· 8 hours agoLoading... Loading... Deep-pocketed investors have adopted a bullish approach towards Moderna MRNA , and it's something market players shouldn't ignore. Our tracking of public ...
Tech Bytes: Moderna partners with OpenAI to expedite drug development processes
Proactive Investors· 18 hours agoModerna, the biotechnology firm best known for its COVID-19 vaccines, has partnered with artificial...
Moderna stock gains on OpenAI deal (NASDAQ:MRNA)
Seeking Alpha· 2 weeks agoModerna (MRNA) stock gains as company announces a deal with AI company OpenAI to accelerate the development of new medicines. Read more here.
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via Yahoo Finance· 5 days agoMerck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698...
